PROTAC : 시장 규모, 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Key Highlights:

• PROTACs is a advanced bustling system formed by three enzymatic reactions involving the ubiquitin-activating enzyme E1, ubiquitin-conjugated enzyme E2, and the ubiquitin-protein ligase E3.
• PROTAC, composed of a target protein ligand, linker, and E3 ligase ligand, represents a novel strategy for breast cancer treatment, specifically targeting breast cancer-related proteins such as ERa and HER2. With the unique advantages of PROTACs, including catalytic efficacy and targeted protein degradation, it has been considered novel therapeutics for targeting breast cancers.
• In 2019, the first PROTAC molecule, Bavdegalutamide (ARV-110), entered clinical testing, and by 2020, these trials provided the first clinical proof-of-concept for the modality targeting two well-established cancer receptors: the estrogen receptor and the androgen receptor. However, Arvinas will prioritize the initiation of an luxdegalutamide (ARV-766) Phase III trial in metastatic Castration-resistant Prostate Cancer (mCRPC) instead of the planned Phase III for bavdegalutamide.
• Vepdegestrant (VEPPANU) became the first FDA-approved PROTAC therapy in May 2026 for the treatment of ER+/HER2- ESR1-mutated breast cancer, representing a significant milestone for this emerging drug modality.
• Emerging players such as Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others are evaluating drugs in clinical trials.

DelveInsight's "PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" report delivers an in-depth understanding of PROTAC, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The PROTAC market report provides insights around existing treatment practices in patients with PROTAC, approved (if any) and emerging PROTAC, market share of individual therapies, patient pool eligible for treatment with PROTAC, along with current and forecasted 7MM PROTAC market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new PROTAC in different geographies, along with insights on PROTAC pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2036

PROTAC Overview

PROTACs is a advanced bustling system formed by three enzymatic reactions involving the ubiquitin-activating enzyme E1, ubiquitin-conjugated enzyme E2, and the ubiquitin-protein ligase E3.

PROTAC, composed of a target protein ligand, linker, and E3 ligase ligand, represents a novel strategy for breast cancer treatment, specifically targeting breast cancer-related proteins such as ERa and HER2. With the unique advantages of PROTACs, including catalytic efficacy and targeted protein degradation, it has been considered novel therapeutics for targeting breast cancers.

Target Patient Pool Analysis

• According to the American Cancer Society (2023), HR+ HER2-negative breast cancer accounts for 65%-70% of all breast cancers, and the incidence increases with increasing age.
• According to Urru et al. (2018), on 841 TNBC patients in Italy, it was found that a maximum number of patients were diagnosed at Stage II, i.e.,~48% of patients, and the least number of patients were diagnosed at Stage IV, i.e., ~1%.
• According to Breastcancer.org (2023), nearly 30% of women diagnosed with early-stage breast cancer develop metastatic disease.
• As per DelveInsight's analysis, the total incident cases of HR+/HER2 breast cancer in the US comprised 215,000 cases in 2025 and are projected to increase during the forecast period.
• As per DelveInsight's analysis, the total incident cases of TNBC in the US comprised 47,000 cases in 2025.

PROTAC Drug Chapters

The drug chapter segment of the PROTAC report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the PROTAC clinical trial details, pharmacological action, agreements and collaborations related to PROTAC, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

PROTAC Marketed Drug

VEPPANU: Arvinas and Pfizer

VEPPANU is an oral estrogen receptor (ER) degrader designed for a specific and stubborn problem: patients with ER+/HER2- breast cancer who develop ESR1 mutations after endocrine therapy. These mutations keep the estrogen receptor constitutively active even when estrogen itself is blocked, which is precisely the kind of resistance mechanism that inhibition alone struggles to overcome, but degradation handles well, because the receptor is gone entirely rather than just occupied.

PROTAC Emerging Drugs

Luxdegalutamide (ARV-766): Arvinas and Novartis

ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor. Preclinically, ARV-766 has demonstrated activity in models of wild type androgen receptor tumors in addition to tumors with androgen receptor mutations or amplification, both common potential mechanisms of resistance to currently available androgen receptor-targeted therapies. It is currently being evaluated in the Phase II for metastatic prostate cancer.

In April 2024, Arvinas entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766., The transaction included an asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis.

ASP3082: Astellas Pharma

ASP3082 (a PROTAC that selectively degrades KRAS G12D protein) is the very first targeted protein degrader, which went into a clinical study phase. This targeted protein degrader has the potential to become a first-in-class treatment for solid tumors associated with the KRAS G12D mutations. A Phase I trial is currently underway in patients with solid tumors having KRAS G12D mutation with anticipated PoC opinion in the first half of the CY2025. The company is preparing for registration trials.

In September 2024, Astellas Pharma presented the preliminary safety and clinical activity of ASP3082 for adults with advanced pancreatic cancer, colorectal cancer, and NSCLC at ESMO 2024. The results demonstrated that ASP3082 has an acceptable safety profile and promising antitumor activity, especially in patients with heavily pretreated pancreatic cancer.

Recent Developments in the PROTAC Market

• In May 2026, FDA approved VEPPANU for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer
• In November 2025, Arvinas presented multiple abstracts on vepdegestrant at the San Antonio Breast Cancer Symposium (SABCS).
• In October 2025, Arvinas announced new patient-reported outcomes data from the Phase III VERITAC-2 clinical trial evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress.
• In March 2025, Arvinas and Pfizer announced positive topline results from the Phase III VERITAC-2 trial, which met its primary endpoint in the ESR1m population, showing a significant improvement in progression-free survival (PFS) compared to fulvestrant, exceeding the pre-specified target Hazard Ratio (HR) of 0.60. However, the trial did not reach statistical significance in the intent-to-treat (ITT) population.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on PROTAC as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of PROTAC, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

PROTAC Market Outlook

This section will include details on changing PROTAC market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

PROTAC Drugs Uptake

This section focuses on the uptake rate of potential PROTAC already launched and expected to be launched in the market during 2022-2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

PROTAC Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

PROTAC Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for PROTAC.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on PROTAC' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on PROTAC addressable patient pool
• A detailed review of the PROTAC market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM PROTAC market.
• Market Size of Inhibitors by therapies and indication will be provided

PROTAC Report Key Strengths

• 11 Years PROTAC Market Forecast
• The 7MM Coverage
• PROTAC Competitive Landscape of current and emerging therapies
• PROTAC Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• PROTAC Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the PROTAC total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for PROTAC market growth?
• Which PROTAC is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of PROTAC?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the PROTAC Market.
• Understand the existing PROTAC market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of PROTAC

4. Key Events

5. PROTAC Market Overview At A Glance

• 5.1. Market Share (%) Distribution of PROTAC By Therapy in 2025
• 5.2. Market Share (%) Distribution of PROTAC By Therapy in 2036

6. Background And Overview

7. Target Population

8. PROTAC Marketed Drugs

• 8.1. Key Competitors
  • 8.1.1. Product Description
  • 8.1.2. Regulatory Milestones
  • 8.1.3. Other Developmental Activities
  • 8.1.4. Ongoing Clinical Development
  • 8.1.5. Safety and Efficacy

9. PROTAC Emerging Drugs

• 9.1. Key Competitors
  • 9.1.1. Product Description
  • 9.1.2. Other Development Activities
  • 9.1.3. Clinical Development
    • 9.1.3.1. Clinical Trials Information
  • 9.1.4. Safety and Efficacy

10. PROTAC: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of PROTAC in the 7MM
  • 10.4.1. Market Size of PROTAC By Therapies In the 7MM
  • 10.4.2. Market Size of PROTAC By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of PROTAC in the United States
  • 10.6.2. Market Size of PROTAC By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of PROTAC in EU4 and the UK
  • 10.7.2. Market Size of PROTAC By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of PROTAC in Japan
  • 10.8.2. Market Size of PROTAC By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight